Open AccessA Case of Papuloerythroderma Successfully Treated with Dupilumab
Author(s) -
Mizuno Ayaka,
Habe Koji,
Matsushima Yoshiaki,
Kondo Makoto,
Yamanaka Keiichi
Publication year - 2022
Publication title -
case reports in dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.338
H-Index - 18
ISSN - 1662-6567
DOI - 10.1159/000524716
Subject(s) - single case
Papuloerythroderma is an erythroderma characterized by the composition of dense paving stone shape papules and intertriginous uninvolved skin on the abdominal wall and is often intractable and accompanied by itching. Topical or oral corticosteroids are treatment measures, but immunosuppressive drugs are sometimes required. Herein, we report a case of papuloerythroderma treated with dupilumab, a completely humanized immunoglobulin monoclonal antibody against interleukin-4 receptor subunit α (IL-4Rα) of IL-4 and IL-13 receptors, with rapid and marked improvement. Dupilumab is one of the treatment options to treat refractory papuloerythroderma.